These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11929387)

  • 21. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.
    Sandborn WJ; Bhandari BR; Fogel R; Onken J; Yen E; Zhao X; Jiang Z; Ge D; Xin Y; Ye Z; French D; Silverman JA; Kanwar B; Subramanian GM; McHutchison JG; Lee SD; Shackelton LM; Pai RK; Levesque BG; Feagan BG
    Aliment Pharmacol Ther; 2016 Jul; 44(2):157-69. PubMed ID: 27218676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis.
    Creed TJ; Norman MR; Probert CS; Harvey RF; Shaw IS; Smithson J; Anderson J; Moorghen M; Gupta J; Shepherd NA; Dayan CM; Hearing SD
    Aliment Pharmacol Ther; 2003 Jul; 18(1):65-75. PubMed ID: 12848627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease.
    Creed TJ; Probert CS; Norman MN; Moorghen M; Shepherd NA; Hearing SD; Dayan CM;
    Aliment Pharmacol Ther; 2006 May; 23(10):1435-42. PubMed ID: 16669958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
    Tew GW; Hackney JA; Gibbons D; Lamb CA; Luca D; Egen JG; Diehl L; Eastham Anderson J; Vermeire S; Mansfield JC; Feagan BG; Panes J; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Kirby JA; Irving PM; De Hertogh G; Van Assche GA; Rutgeerts P; O'Byrne S; Hayday A; Keir ME
    Gastroenterology; 2016 Feb; 150(2):477-87.e9. PubMed ID: 26522261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
    Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
    Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
    Garnock-Jones KP
    BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study.
    Vermeire S; Ghosh S; Panes J; Dahlerup JF; Luegering A; Sirotiakova J; Strauch U; Burgess G; Spanton J; Martin SW; Niezychowski W
    Gut; 2011 Aug; 60(8):1068-75. PubMed ID: 21317177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.
    Yoshimura N; Watanabe M; Motoya S; Tominaga K; Matsuoka K; Iwakiri R; Watanabe K; Hibi T;
    Gastroenterology; 2015 Dec; 149(7):1775-1783.e2. PubMed ID: 26327130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.
    Sandborn WJ; Colombel JF; Frankel M; Hommes D; Lowder JN; Mayer L; Plevy S; Stokkers P; Travis S; Van Assche G; Baumgart DC; Targan SR
    Gut; 2010 Nov; 59(11):1485-92. PubMed ID: 20947884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
    Reinisch W; Sandborn WJ; Hommes DW; D'Haens G; Hanauer S; Schreiber S; Panaccione R; Fedorak RN; Tighe MB; Huang B; Kampman W; Lazar A; Thakkar R
    Gut; 2011 Jun; 60(6):780-7. PubMed ID: 21209123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
    Sands BE; Tremaine WJ; Sandborn WJ; Rutgeerts PJ; Hanauer SB; Mayer L; Targan SR; Podolsky DK
    Inflamm Bowel Dis; 2001 May; 7(2):83-8. PubMed ID: 11383595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
    Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody].
    Asakura H
    Nihon Rinsho; 2002 Mar; 60(3):531-8. PubMed ID: 11904969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis.
    Fiorino G; Gilardi D; Naccarato P; Sociale OR; Danese S
    Dig Liver Dis; 2014 Apr; 46(4):330-4. PubMed ID: 24462118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.